AtriCure Inc. (NASDAQ:ATRC) Q1 2022 Results Conference Call May 3, 2022 4:30 PM ET
Company Participants
Marissa Bych - Gilmartin Group
Michael Carrel - President, CEO
Angela Wirick - CFO
Conference Call Participants
Robbie Marcus - JPMorgan
Danielle Antalffy - SVB Leerink
John McAulay - Stifel
Sam Eiber - BTIG
David Saxon - Needham
Matthew O'Brien - Piper Sandler
Suraj Kalia - Oppenheimer
Operator
Good afternoon, and welcome to AtriCure's First Quarter 2022 Earnings Conference Call. My name is Jeff and I will be your coordinator for call today. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
I would now like to hand the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Marissa Bych
Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call (513) 755-4136 to have one e-mailed to you.
Before we begin today, let me remind you that, the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings.
These statements include, but are not limited to financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, including the adoption of the Hybrid AF procedure and future product approvals, clearances and reimbursement. AtriCure's results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statements.
Additionally, we refer to non-GAAP financial measures, specifically revenue reported on a constant currency basis, adjusted EBITDA and adjusted loss per share. A reconciliation of these non-GAAP financial measures with the most directly comparable GAAP measures is included in our press release, which is available on our website.
And with that, I would like to turn the call over to Mike Carrel, President and Chief Executive Officer. Mike?
Michael Carrel
Good afternoon, everyone, and thank you for joining us. We hope that you're all well.
I'm pleased to share that AtriCure delivered an excellent first quarter results, as growth across key product lines and geographies demonstrated the strength of our portfolio, despite challenging conditions to begin the quarter. We generated $74.6 million in revenue, reflecting growth of approximately 26% over the first quarter of 2021. Highlights for the quarter included the growth of our cryoSPHERE probe for pain management and strength in our AtriClip product line, showing the broad appeal and continued adoption by new and existing customers.